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Background: This study examines racial disparities in advanced heart failure patients treated with left ventricular assist devices (LVAD). We 
hypothesize that specialized treatment in a comprehensive heart failure/assist device program results in similar survival amongst various ethnicities.
methods: A retrospective analysis of HeartMate II clinical trial database was performed. Patients were categorized as Caucasians (Cau), African 
Americans (AA) and Others (Hispanics, Asians, ethnic minorities). Variables analyzed included demographics, 2-year survival and right heart failure 
and HeartMate II risk score (age, albumin, creatinine, INR).
results: 637 of the 1126 patients (53.6%) received LVAD as Destination Therapy.The HeartMate II risk score was significantly higher compared to 
other groups (p=0.004). No difference was seen in baseline renal or hepatic profiles. Survival by Kaplan-Meier analysis revealed a higher unadjusted 
survival (P<0.001) for the Others compared to AA and Cau. 
Race
Age
(Years)
Female Sex
(N,%)
LVEF(%)
Ischemic 
Etiology
Right Heart Failure 
(events/patient year)
HeartMate II Risk 
Score
2-year survival (%)
Caucasian
(N=830)
61.0±12.3 150(18%) 17.0± 6.1 517 (62%) 200 (0.15) 1.85±1.28 58±2.0%
African American 
(N=215)
49.8±14.7 83 (39%) 15.3± 5.7 44 (20%) 58 (0.14) 1.65±0.98 67±3.8%
Others (N=81) 56.3±15.9 17 (21%) 17.9± 5.7 38 (47%) 21 (0.13) 1.64±0.93 77±5.3%
P value <0.001 <0.001 <0.001 <0.001 0.73 0.004
p< 0.001 
(unadjusted)
This survival advantage was lost after adjustment for female gender, ischemic etiology and HeartMate II risk score. There was no difference in survival 
between the AA and Cau either (p=0.25).
conclusions: In patients with advanced heart failure, no difference in survival exists based on ethnicity. This is probably reflective of standardized 
medical care in treating all patient cohorts.
